Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Frequency of each adverse event in the mangosteen and placebo groupsAdverse event organ codeAdverse event symptomsPlaceboMangosteenTotalEar and labyrinth disorders (10013993)Tinnitus, vertigo235Endocrine disorders (10014698)Hypothyroidism213Gastrointestinal disorders (10017947)Abdominal discomfort, abdominal pain, bloating, blood in stool, constipation, menstrual pain, diarrhoea, diverticulitis, gastroenteritis, gastrointestinal pain, heartburn, indigestion, nausea, stomach ache, vomiting, gastrointestinal upset343670General disorders and administration site conditions (10018065)Breast swelling, fever, sweating, tiredness/fatigue, decreased appetite12416Immune system disorders (10021428)Hay fever325Infections and infestations (10021881)Infection, sinusitis, urinary tract infection, viral infection, cold sore (mouth)6814Investigations (10022891)Colonoscopy, weight gain, weight loss617Metabolism and nutrition disorders (10027433)Hyperglycaemia, hypoglycaemia, vitamin D deficiency819Musculoskeletal and connective tissue disorders (10028395)Back pain, knee pain, muscle pain, fibromyalgia, ligament injury7714Nervous system disorders (10029205)Dizziness, headache, migraine161632Psychiatric disorders (10037175)Depression, depression worsening, elevated mood, hallucination, hypomania, mania, panic attack, psychotic, suicidal ideation151934Renal and urinary disorders (10038359)Dysuria, elevated LFTs044Respiratory, thoracic and mediastinal disorders (10038738)Chest infection, bloating, cough, upper respiratory infection, cold, cough, flu, sinus infection, sore throat, bronchitis303363Skin and subcutaneous tissue disorders (10040785)Rash022 Total 141 137 278 LFT, liver function test.
Source: Adverse events. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Other blinding reported · Human research reported
Reported blinded roles: participants.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
(mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial
Source: Article title.
Participants aged 18 years and older with a diagnosis of bipolar I or II and with at least moderate depressive symptoms were eligible for the study.
Source: Abstract.
The participants, researchers and statistician were blind to group allocation.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial
Randomised controlled trial · The British Journal of Psychiatry · 2025
Original publication title
The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
The current 28-week randomised, multisite, double-blind, placebo-controlled trial investigated mangosteen pericarp extract as an adjunct to treatment-as-usual for treatment of bipolar depression.
Source: AimsAbstract: What methods does the paper describe?
This trial was prospectively registered on the Australia New Zealand Clinical Trials Registry (no. ACTRN12616000028404). Participants aged 18 years and older with a diagnosis of bipolar I or II and with at least moderate depressive symptoms were eligible for the study. A total of 1016 participants were initially approached or volunteered for the study, of whom 712 did not progress to screening, with an additional 152 screened out. Seventy participants were randomly allocated to mangosteen and 82 to a placebo control.
Fifty participants in the mangosteen and 64 participants in the placebo condition completed the treatment period and were analysed.
Source: MethodAbstract: Results
Results indicated limited support for the primary hypothesis of superior depression symptom reduction following 24 weeks of treatment. Although overall changes in depressive symptoms did not substantially differ between conditions over the course of the trial, we observed significantly greater improvements for the mangosteen condition at 24 weeks, compared with baseline, for mood symptoms, clinical impressions of bipolar severity and social functioning compared with controls. These differences were attenuated at week 28 post-discontinuation assessment.
Source: ResultsAbstract: Conclusions
Adjunctive mangosteen pericarp treatment appeared to have limited efficacy in mood and functional symptoms associated with bipolar disorder, but not with manic symptoms or quality of life, suggesting a novel therapeutic approach that should be verified by replication.
Source: ConclusionsAuthors’ abstract
Background
Bipolar depression remains difficult to treat, and people often experience ongoing residual symptoms, decreased functioning and impaired quality of life. Adjunctive therapies targeting novel pathways can provide wider treatment options and improve clinical outcomes. Garcinia mangostana Linn. (mangosteen) pericarp has serotonogenic, antioxidant anti-inflammatory and neurogenic properties of relevance to the mechanisms of bipolar depression.
Aims
The current 28-week randomised, multisite, double-blind, placebo-controlled trial investigated mangosteen pericarp extract as an adjunct to treatment-as-usual for treatment of bipolar depression.
Method
This trial was prospectively registered on the Australia New Zealand Clinical Trials Registry (no. ACTRN12616000028404). Participants aged 18 years and older with a diagnosis of bipolar I or II and with at least moderate depressive symptoms were eligible for the study. A total of 1016 participants were initially approached or volunteered for the study, of whom 712 did not progress to screening, with an additional 152 screened out. Seventy participants were randomly allocated to mangosteen and 82 to a placebo control.
Fifty participants in the mangosteen and 64 participants in the placebo condition completed the treatment period and were analysed.
Results
Results indicated limited support for the primary hypothesis of superior depression symptom reduction following 24 weeks of treatment. Although overall changes in depressive symptoms did not substantially differ between conditions over the course of the trial, we observed significantly greater improvements for the mangosteen condition at 24 weeks, compared with baseline, for mood symptoms, clinical impressions of bipolar severity and social functioning compared with controls. These differences were attenuated at week 28 post-discontinuation assessment.
Conclusions
Adjunctive mangosteen pericarp treatment appeared to have limited efficacy in mood and functional symptoms associated with bipolar disorder, but not with manic symptoms or quality of life, suggesting a novel therapeutic approach that should be verified by replication.
Publication and source details
Original title: The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial
Olivia M. Dean; Susan M. Cotton; Melanie M. Ashton; Alyna Turner; Lucy Saunders; Chee H. Ng; Malcolm Hopwood; Seetal Dodd; Jon-Paul Khoo; Adam J. Walker; Mary Lou Chatterton; Bianca E. Kavanagh; Sarah E. Nadjidai; Samantha L. Lo Monaco; Brian H. Harvey; Gin S. Malhi; Ellie Brown; David R. Skvarc; Danica Diao; Felice N. Jacka; Jerome Sarris; Nathan L. Dowling; Michael Berk
The British Journal of Psychiatry · 2025
Correspondence: Olivia M. Dean. Email: o.dean@deakin.edu.au© The Author(s) 20252025The Author(s)https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T04:05:32.071829+00:00
DOI: 10.1192/bjp.2025.108 · PMC12628125